The safety data are in some respects similar to those seen with other biologics in RA, including infections, although some IL-6 pathway-dependent effects are also seen, including a decrease in neutrophils and an increase in lipids, without a distinct cardiovascular safety risk. This evidence concerns the gene IL6 and infection.